AI-generated research brief — verify at source
Extended-Release Clonidine Reduces ADHD Symptoms in Chinese Children Over Six Weeks
In a placebo-controlled trial of Chinese children and adolescents with ADHD, once-daily extended-release clonidine produced a meaningfully greater reduction in total symptom scores compared with placebo (least squares mean change: −17.5 versus −10.3 on the SNAP-IV scale). The findings support clonidine extended-release as a viable nonstimulant treatment option in this population, though the small sample size and short duration require cautious interpretation.
What Was Studied
This trial investigated whether clonidine hydrochloride extended-release tablets (CLON-XR), taken as monotherapy, could safely and effectively reduce ADHD symptoms in Chinese children and adolescents. The study addresses a specific evidence gap: despite ADHD being a common neurodevelopmental condition in this age group, randomized controlled trial data supporting pharmacological treatment in Chinese pediatric populations has remained limited.
How It Was Studied
This was a phase 3, multicenter, randomized, double-blind, placebo-controlled trial conducted over six weeks. A total of 75 patients aged 6 to 17 years with a confirmed ADHD diagnosis were enrolled and assigned in a 2:1 ratio to receive either once-daily CLON-XR (titrated to a target dose of 0.2 mg/day) or placebo. The primary efficacy measure was the change from baseline to week 5 in the Swanson, Nolan, and Pelham Rating Scale Version IV (SNAP-IV) total score, a validated instrument for capturing ADHD symptom severity across inattention and hyperactivity-impulsivity domains. Secondary endpoints included SNAP-IV subscale scores, the Clinical Global Impression–Severity (CGI-S) scale, and the Clinical Global Impression–Improvement (CGI-I) scale, along with comprehensive safety monitoring.
What Was Observed
- CLON-XR produced a substantially larger improvement in overall ADHD symptom burden than placebo by week 5, with least squares mean reductions of −17.5 points versus −10.3 points on the SNAP-IV total score. This difference represents a clinically meaningful separation between active treatment and control on the primary endpoint.
- Secondary outcome measures, including SNAP-IV subscale scores for inattention and hyperactivity-impulsivity, as well as clinician-rated CGI-S and CGI-I scores, also favored CLON-XR over placebo, suggesting broad symptomatic improvement rather than improvement in a single symptom domain.
- CLON-XR was reported to be well tolerated throughout the trial period, with the safety profile consistent with acceptable tolerability in the pediatric age range studied. No safety signals were identified that would contraindicate its use in this population based on the six-week observation window.
Why This Matters
Randomized controlled trial evidence for pharmacological ADHD treatment specifically in Chinese children and adolescents has been scarce, leaving clinicians in China with limited locally validated options. This trial provides phase 3 evidence that a nonstimulant agent — CLON-XR — can produce significant symptom reduction in this population, potentially broadening the treatment landscape beyond stimulant medications. The authors also highlight that further investigation in longer-term and real-world settings will be necessary to understand the durability and broader applicability of these findings.
How to Read This Result
Given the small total sample of 75 participants, the short six-week observation period, and the single-country design, these results should be regarded as preliminary evidence requiring replication in larger, longer, and more diverse trials before broad clinical conclusions can be drawn.
Limitations
The authors explicitly note that further investigations in longer-term and real-world settings are needed, implying that the six-week duration and controlled trial conditions limit the ability to generalize findings to everyday clinical practice. The relatively small sample size (75 participants total) also constrains the precision of effect estimates and the ability to detect less common adverse events. No additional limitations beyond these were explicitly stated in the abstract.